Personalized treatments for mCRC disease are today limited to a small number of drugs towards molecular targets such as anti-VEGF, anti-EGFR for RAS wild-type tumors, encorafenib for BRAF (V600E) mutated tumors, programmed death-ligand 1/programmed cell death-1(PDL-1/PD-1) inhibitors for mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) tumors, and possibly KRAS tyrosine kinase inhibitors for G12C KRAS mutated tumors [12]. The gene discussed is KRAS; the disease is hyperinsulinemic hypoglycemia, familial, 4.